Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer’s disease model

BACKGROUND: Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that lacks any disease-modifying drug for the prevention and treatment. Edaravone (EDR), an approved free radical scavenger, has proven to have potential against AD by targeting multiple key pathologies including amyloi...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Ankit, Kathawala, Krishna, Li, Jintao, Chen, Chi, Shan, Zhengnan, Cao, Xia, Wang, Yan-Jiang, Garg, Sanjay, Zhou, Xin-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042531/
https://www.ncbi.nlm.nih.gov/pubmed/30022810
http://dx.doi.org/10.2147/DDDT.S161944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042531/
https://www.ncbi.nlm.nih.gov/pubmed/30022810
http://dx.doi.org/10.2147/DDDT.S161944

Ejemplares similares